| Patricia M Wortley, AUD | |
|
250 Mcdavid Blvd, Grayson, KY 41143-1603 | |
| (606) 474-7835 | |
| Not Available |
| Full Name | Patricia M Wortley |
|---|---|
| Gender | Female |
| Speciality | Qualified Audiologist |
| Experience | 40 Years |
| Location | 250 Mcdavid Blvd, Grayson, Kentucky |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144692997 | NPI | - | NPPES |
| 7100411460 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | 148705 (Kentucky) | Primary |
| 231H00000X | Audiologist | SLPAUD00193936 (Kentucky) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Jeffrey Leider Md Pllc | 0941469621 | 10 |
News Archive
Optimism surrounding the science of HIV treatment and prevention "is tempered by less auspicious trends, particularly shrinking budgets for global health in the U.S. and around the world," Victoria Fan, Amanda Glassman, and Rachel Silverman of the Center for Global Development (CGD) write in the center's "Global Health Policy" blog.
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that they will further expand their collaboration to include the development of Lu AF20513, an investigational vaccine candidate for Alzheimer's disease.
MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced the initiation of the OPTION (Optimal Improvement of Vein Graft Patency Long Term by the Implementation Of Novel Endoscopic Harvesting Techniques) study. This clinical trial is designed to evaluate the equivalence of Endoscopic Vessel Harvesting (EVH) in Coronary Artery Bypass Graft (CABG) surgery compared with historical data for open vein harvesting. David Moore, M.D., of THE HEART HOSPITAL Baylor Plano is the principal investigator for the OPTION trial.
The AUA is pleased to announce their new Guideline on the Management of Nonmuscle Invasive Bladder Cancer. Each year, more than 60,000 people are diagnosed with bladder cancer, which has been linked to a number of risk factors, including cigarette smoking and exposure to hazardous chemicals.
News outlets report on developments regarding state online insurance marketplaces.
› Verified 8 days ago
| Provider Name | Jeffrey Leider Md Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1902175318 PECOS PAC ID: 0941469621 Enrollment ID: O20120315000730 |
News Archive
Optimism surrounding the science of HIV treatment and prevention "is tempered by less auspicious trends, particularly shrinking budgets for global health in the U.S. and around the world," Victoria Fan, Amanda Glassman, and Rachel Silverman of the Center for Global Development (CGD) write in the center's "Global Health Policy" blog.
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that they will further expand their collaboration to include the development of Lu AF20513, an investigational vaccine candidate for Alzheimer's disease.
MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced the initiation of the OPTION (Optimal Improvement of Vein Graft Patency Long Term by the Implementation Of Novel Endoscopic Harvesting Techniques) study. This clinical trial is designed to evaluate the equivalence of Endoscopic Vessel Harvesting (EVH) in Coronary Artery Bypass Graft (CABG) surgery compared with historical data for open vein harvesting. David Moore, M.D., of THE HEART HOSPITAL Baylor Plano is the principal investigator for the OPTION trial.
The AUA is pleased to announce their new Guideline on the Management of Nonmuscle Invasive Bladder Cancer. Each year, more than 60,000 people are diagnosed with bladder cancer, which has been linked to a number of risk factors, including cigarette smoking and exposure to hazardous chemicals.
News outlets report on developments regarding state online insurance marketplaces.
› Verified 8 days ago
| Provider Name | Special Care Hearing Of Kentucky Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1023412251 PECOS PAC ID: 1153647557 Enrollment ID: O20150302002113 |
News Archive
Optimism surrounding the science of HIV treatment and prevention "is tempered by less auspicious trends, particularly shrinking budgets for global health in the U.S. and around the world," Victoria Fan, Amanda Glassman, and Rachel Silverman of the Center for Global Development (CGD) write in the center's "Global Health Policy" blog.
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that they will further expand their collaboration to include the development of Lu AF20513, an investigational vaccine candidate for Alzheimer's disease.
MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced the initiation of the OPTION (Optimal Improvement of Vein Graft Patency Long Term by the Implementation Of Novel Endoscopic Harvesting Techniques) study. This clinical trial is designed to evaluate the equivalence of Endoscopic Vessel Harvesting (EVH) in Coronary Artery Bypass Graft (CABG) surgery compared with historical data for open vein harvesting. David Moore, M.D., of THE HEART HOSPITAL Baylor Plano is the principal investigator for the OPTION trial.
The AUA is pleased to announce their new Guideline on the Management of Nonmuscle Invasive Bladder Cancer. Each year, more than 60,000 people are diagnosed with bladder cancer, which has been linked to a number of risk factors, including cigarette smoking and exposure to hazardous chemicals.
News outlets report on developments regarding state online insurance marketplaces.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Patricia M Wortley, AUD 12910 Shelbyville Rd, Suite 300, Louisville, KY 40243-1593 Ph: (502) 244-2441 | Patricia M Wortley, AUD 250 Mcdavid Blvd, Grayson, KY 41143-1603 Ph: (606) 474-7835 |
News Archive
Optimism surrounding the science of HIV treatment and prevention "is tempered by less auspicious trends, particularly shrinking budgets for global health in the U.S. and around the world," Victoria Fan, Amanda Glassman, and Rachel Silverman of the Center for Global Development (CGD) write in the center's "Global Health Policy" blog.
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that they will further expand their collaboration to include the development of Lu AF20513, an investigational vaccine candidate for Alzheimer's disease.
MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced the initiation of the OPTION (Optimal Improvement of Vein Graft Patency Long Term by the Implementation Of Novel Endoscopic Harvesting Techniques) study. This clinical trial is designed to evaluate the equivalence of Endoscopic Vessel Harvesting (EVH) in Coronary Artery Bypass Graft (CABG) surgery compared with historical data for open vein harvesting. David Moore, M.D., of THE HEART HOSPITAL Baylor Plano is the principal investigator for the OPTION trial.
The AUA is pleased to announce their new Guideline on the Management of Nonmuscle Invasive Bladder Cancer. Each year, more than 60,000 people are diagnosed with bladder cancer, which has been linked to a number of risk factors, including cigarette smoking and exposure to hazardous chemicals.
News outlets report on developments regarding state online insurance marketplaces.
› Verified 8 days ago